Intended Audience
- Researchers and scientists familiar with next-generation sequencing (NGS) and genomic technologies who want to understand technological innovation and the changing competitive landscape of the sequencing industry.
- Readers interested in the founding history, technology development, product strategy, financing, and business expansion of Ultima Genomics.
- Professionals interested in how emerging companies navigate the transition from research and development to commercialization in genomics, single-cell biology, proteomics, and cancer diagnostics.
Executive Summary
- Ultima Genomics is a high-throughput, low-cost DNA sequencing company founded in 2016 by Gilad Almogy, an entrepreneur with a background in semiconductor manufacturing technology.
- After emerging from stealth in 2022 with approximately $600 million in cumulative funding and the promise of the "$100 genome," the company commercialized the UG 100 in 2024, introduced Solaris in 2025, and launched the UG200 series in 2026. It subsequently announced the "$60 genome."
- Its application focus has expanded from demonstrating cost advantages in whole-genome sequencing (WGS) to single-cell RNA sequencing, molecular residual disease (MRD), proteomics, population-scale genomics, and AI-driven multi-omics.
- The company has addressed technical limitations while expanding through collaborations with major research institutions and clinical testing organizations. However, instrument utilization, profitability, and broad clinical adoption remain important areas requiring further evaluation.
- Ultima's long-term success may depend less on achieving the lowest sequencing cost alone and more on becoming a widely adopted infrastructure platform for large-scale molecular measurement.
1. Understanding Ultima Genomics: An Overview
Ultima Genomics is a US-based DNA sequencing company founded in 2016.
Its defining characteristic is an attempt to fundamentally change the economics of sequencing rather than incrementally improve conventional NGS technologies.
Founder Gilad Almogy previously held senior executive positions at Applied Materials, a leading manufacturer of semiconductor equipment.
Ultima developed a proprietary sequencing architecture combining open fluidics, wafer-based sequencing, mostly natural sequencing-by-synthesis (mnSBS), and computational base calling. This approach was designed to overcome limitations associated with conventional flow cells and sequencing-by-synthesis chemistry. [1][2][3]
Understanding the company's development requires looking beyond the simple idea that it built a DNA sequencer cheaper than Illumina's products.
Its history can be divided into three broad phases.
Phase One (2016–2022): Developing technology to transform sequencing economics
During this phase, Ultima brought concepts from the semiconductor industry into NGS, redesigning the flow cell architecture, chemistry, optics, computation, and other core components.
Phase Two (2022–2024): Transitioning from technological validation to commercialization
Ultima emerged from stealth with its "$100 genome" proposition, conducted scientific validation with institutions such as the Broad Institute, and commercialized its first sequencing system, the UG 100.
Phase Three (2025–2026): Evolving from a low-cost NGS instrument provider into a large-scale multi-omics platform
The company expanded its technology through Solaris, UG200, paired-end sequencing, and high-accuracy rare variant detection while entering markets such as oncology, drug discovery, population genomics, single-cell analysis, and proteomics.
From a financing perspective, Ultima disclosed approximately $600 million in cumulative funding when it emerged from stealth in 2022 and reported more than $700 million in cumulative funding by 2026.
Its investors include Lightspeed Venture Partners, Khosla Ventures, Andreessen Horowitz, General Atlantic, and Founders Fund. [1][4]
1.1 Timeline: From Founding to 2026
| Period | Major Developments | Business Significance |
|---|---|---|
| 2016–2017 | Founded by Gilad Almogy and colleagues; early investment from Lightspeed and others | Began developing a fundamentally new sequencing architecture |
| 2018–2021 | Developed instruments, chemistry, and software while operating in stealth mode | Reduced technological risks through vertically integrated system development |
| 2022 | Announced the $100 genome and approximately $600 million in cumulative funding | Entered the public scientific and investment landscape |
| 2023 | Strengthened technical and commercial leadership; advanced application development with external partners | Prepared for the transition from R&D to commercialization |
| 2024 | Commercialized the UG 100; sequencing service providers began offering access | Began validating the technology through commercial operations |
| 2025 | Introduced UG 100 Solaris and expanded its global service provider network | Increased throughput, reduced costs, and broadened customer access |
| 2026 | Introduced the UG200 series, Solaris 2.0, and paired-end sequencing | Expanded accuracy, flexibility, and application coverage |
In October 2026, Ultima announced paired-end sequencing and Solaris 2.0 Max, introducing its "$60 genome" proposition.
This continued the company's cost-reduction trajectory from the $100 genome in 2022 to the $80 genome in 2025. [5][6]
However, evaluating the company's commercial success requires distinguishing among sequencing consumable costs, performance requirements for clinical applications, actual customer adoption, and profitability.
In particular, a "$60 genome" does not mean that a complete clinical WGS test can be delivered for $60.
2. Why Was Ultima Genomics Founded?
2.1 A Founder from Semiconductor Engineering, Not Traditional Genomics
Gilad Almogy, founder and CEO of Ultima Genomics, earned a PhD in Applied Physics from the California Institute of Technology.
He worked at Applied Materials from 1997 to 2009, eventually serving as Senior Vice President.
He subsequently founded Cogenra Solar, a solar energy company acquired by SunPower in 2015.
In 2016, Almogy founded Ultima Genomics. [7]
This background is significant.
NGS development often begins with expertise in molecular biology, enzyme engineering, or DNA chemistry.
Almogy approached the problem from a different perspective, drawing on semiconductor manufacturing concepts such as large-area substrate processing, fluid control, optical inspection, and sophisticated automation.
From this perspective, conventional NGS systems presented several fundamental limitations:
- Flow cell size and architecture constrain the number of DNA molecules that can be processed in parallel.
- Complex reagent delivery systems increase instrument and operating costs.
- SBS chemistry involving fluorescently labeled nucleotides and reversible terminators introduces limitations in cost and reaction speed.
- Optimizing imaging, reagent exchange, nucleotide incorporation, and base calling independently may not sufficiently reduce total system costs.
Ultima's central idea was not to improve these components individually but to redesign the entire sequencing architecture, integrating chemistry, fluidics, optics, and computation.
2.2 Redesigning the Economics of Scale Rather Than Improving Conventional NGS
Three major technological elements underpin Ultima's sequencing platform.
1. Open Fluidics and Wafer-Based Sequencing
Unlike conventional enclosed flow cells, Ultima uses a large circular wafer that rotates while reagents are delivered across its surface.
The concept resembles spin coating in semiconductor manufacturing.
This architecture allows relatively efficient processing of large surface areas and enables different approaches to optimizing reagent consumption, fluid control, and image acquisition.
2. Mostly Natural Sequencing-by-Synthesis (mnSBS)
Ultima's chemistry uses predominantly natural nucleotides, with a relatively small proportion of fluorescently labeled nucleotides.
Unlike conventional SBS, in which nucleotide incorporation is tightly controlled one base at a time, this approach uses non-terminating extension reactions.
Optical signals generated during these reactions are analyzed to infer the incorporated bases.
3. Computational Base Calling
Because Ultima's chemistry generates signals different from those produced by conventional SBS systems, algorithms and machine learning play important roles in converting these signals into accurate sequences.
Ultima's competitive advantage therefore does not rest on a single enzyme or reagent.
Instead, it depends on integrated optimization across the instrument, chemistry, image acquisition, and computational processing.
This approach was described in research published by scientists from Ultima and the Broad Institute in 2022. [2][3]
2.3 Why Did Ultima Remain in Stealth Mode for Nearly Six Years?
Ultima spent approximately six years developing its technology between its founding in 2016 and its public announcement in May 2022.
Although public information about internal decisions during this period is limited, several explanations are plausible.
First, unlike ordinary software products, DNA sequencers require the coordinated development of instruments, chemistry, manufacturing processes, and analysis software.
Success in any one component does not automatically produce a commercially viable sequencing system.
Second, existing NGS customers do not switch platforms based on price alone.
Compatibility with existing libraries, sequencing accuracy, bioinformatics workflows, and reproducibility must be extensively validated.
Third, sequencing instrument development is capital-intensive.
Substantial investment is required not only for research and development but also for instrument prototyping, manufacturing infrastructure, reagent production, and validation with early customers.
It was therefore strategically reasonable to secure substantial funding and conduct validation with major research institutions before publicly introducing the technology.
By the time Ultima announced its platform in 2022, more than 200 human whole-genome datasets had already been generated at the Broad Institute. [1]
This suggests that technical validation was central to the company's early development strategy.
However, public information is insufficient to reconstruct specific engineering failures, strategic changes, or financing difficulties during the stealth period.
3. How Did Ultima's Technology and Products Evolve?
3.1 2022: The $100 Genome as a Technological Declaration
On May 31, 2022, Ultima emerged from stealth and announced a new sequencing platform capable of delivering the "$100 genome."
At that stage, the company had made substantial progress in technological validation, but the platform had not yet become a broadly available commercial product.
The publicly presented datasets included WGS, single-cell RNA sequencing, and cancer epigenetics applications.
This demonstrated that Ultima did not intend to limit its technology to a single genomic application. [1][2]
3.2 2024: Commercialization of the UG 100
In February 2024, Ultima introduced its first commercial sequencing system, the UG 100.
The UG 100 was designed to generate approximately 6–8 billion reads per wafer and deliver a $100 genome at 30× WGS coverage.
Its principal target customers were large research facilities processing substantial numbers of samples.
With a stated maximum annual capacity of approximately 20,000 human genomes at 30× coverage, the platform emphasized high throughput and low sequencing costs compared with conventional NGS systems. [8]
3.3 2025: Evolution to UG 100 Solaris
In February 2025, Ultima commercially introduced UG 100 Solaris.
This represented more than a product rebranding.
The new version incorporated improvements in chemistry, software, and workflows.
One major improvement was the increase in output from 6–8 billion reads to approximately 10–12 billion reads per wafer.
Sequencing costs were also reduced by approximately 20%, bringing the advertised cost from $100 to $80 per genome.
Ultima also announced improvements in rare variant detection, including a fivefold increase in yield for its SNVQ60 ppmSeq mode and the ability to generate 30× coverage from 2 ng of DNA.
In addition, the company announced early access to Solaris Boost mode, targeting up to 100 billion reads per day for selected short-read applications. [6]
3.4 2026: The UG200 Series and Solaris 2.0
In February 2026, Ultima announced its second-generation sequencing platform, the UG200 series.
The new generation introduced a smaller instrument footprint, faster processing, improvements in amplification chemistry, and greater operational flexibility.
The UG200 supports a single-wafer configuration, while the UG200 Ultra supports a dual-wafer configuration.
The platform was designed to generate up to 20 billion reads per wafer, with the UG200 Ultra targeting annual throughput exceeding 60,000 human genomes at 30× coverage.
In October 2026, Solaris 2.0 Max and paired-end sequencing were commercially introduced, accompanied by the announcement of the $60 genome. [5][9]
The major product generations can be compared as follows.
| Metric | UG 100 (2024) | UG 100 Solaris (2025) | UG200 Generation (2026) |
|---|---|---|---|
| Reads per wafer | 6–8 billion | 10–12 billion | Up to 20 billion |
| Advertised cost per 30× WGS | $100 | $80 | $60 |
| Maximum annual 30× WGS throughput | Approximately 20,000 | More than 30,000 | More than 60,000 (Ultra) |
| Main development | Initial commercialization | Chemistry and software improvements | Redesign of instrument, amplification, and analysis |
These figures represent company-reported specifications or costs based on consumable pricing.
The maximum annual throughput values depend on different instrument configurations and operating assumptions, and they should not be interpreted as the total cost of a clinical sequencing test.
Likewise, the advertised $60 figure does not include every cost associated with sample preparation, equipment depreciation, facility operation, data storage, and clinical quality assurance.
3.5 The UG200 Addressed More Than Sequencing Cost
The UG200 series incorporated several improvements addressing practical limitations of the original UG 100.
Improved Amplification
The original platform required processes and dedicated equipment associated with emulsion PCR (ePCR).
The UG200 introduced a new isothermal amplification approach.
This was intended not only to simplify workflows but also to improve coverage uniformity, particularly in GC-rich and complex genomic regions.
Flexible Instrument Configurations
The UG200 supports single-wafer operation, while the UG200 Ultra supports dual-wafer operation.
In February 2026, the company announced a starting instrument price of approximately $850,000.
Compared with the reported price of approximately $1.5 million for the original platform, this represented a reduction in the initial investment required for adoption.
Paired-End Sequencing
In October 2026, Ultima commercially introduced paired-end sequencing on the UG200 platform.
This was not simply an additional feature.
It represented an important improvement in compatibility with existing WGS, structural variant analysis, and clinical bioinformatics workflows.
Smaller Footprint and Higher Speed
Ultima also improved instrument size, processing capacity, and operational efficiency.
These changes are important for reducing the total cost of ownership (TCO) in sequencing laboratories.
With its second-generation platform, Ultima placed greater emphasis on practical laboratory usability alongside higher throughput. [5][9]
Taken together, these developments suggest a strategic shift.
While the early company prioritized achieving extremely low sequencing costs, later product generations placed increasing emphasis on compatibility with established research and clinical workflows.
4. How Did Ultima's Application Focus Change?
One of the most interesting aspects of Ultima's business strategy is the evolution of its target applications.
The broad trajectory has been a shift from demonstrating cost advantages through WGS toward expanding into applications that consume enormous amounts of sequencing data.
4.1 Early Focus: Demonstrating Cost Advantages Through WGS
The rationale for announcing the "$100 genome" in 2022 was straightforward.
Human WGS provides an easily understandable benchmark for comparing NGS throughput and costs.
However, WGS alone does not necessarily guarantee a large and profitable business.
Although cost per sample is important in population-scale genomics, customers also incur expenses related to data processing, quality control, and sample preparation.
Ultima therefore demonstrated the applicability of its technology beyond WGS from an early stage.
4.2 Single-Cell RNA Sequencing: A Crucial Early Scientific Validation
The Nature Biotechnology paper titled "Mostly natural sequencing-by-synthesis for scRNA-seq using Ultima sequencing," published online in September 2022, provides important insight into Ultima's early strategy. [2]
In this study, researchers from the Broad Institute and collaborating institutions compared multiple single-cell RNA-seq libraries sequenced using Ultima and Illumina platforms.
The results demonstrated strong agreement in representative analyses such as cell classification, gene expression measurement, and Perturb-seq.
However, the study also identified limitations, including reduced quality near poly(T) regions in 3′ libraries and constraints associated with single-end sequencing.
The significance of this research was not that Ultima had already achieved equivalent performance across all NGS applications.
Rather, it showed that applications based on large-scale read counting could potentially benefit from substantial cost advantages while tolerating certain technical limitations.
This appears to have been a well-chosen early market.
In single-cell expression profiling, the main analytical interests often involve read counting, unique molecular identifiers (UMIs), and cell barcodes.
Accurate reconstruction of every genomic region is not required.
Consequently, even Ultima's early technology could deliver significant value in these applications.
4.3 2023–2024: Expansion into Oncology and MRD
Another important application was cancer diagnostics, particularly molecular residual disease (MRD).
Several collaborations were announced during 2023 and 2024.
| Partner | Period | Objective |
|---|---|---|
| Quest Diagnostics | January 2024 | Evaluate potential applications involving Haystack MRD technology |
| Labcorp | July 2024 and expanded collaboration | Combine WGS-based MRD approaches with Plasma Detect |
| Genome Insight / Inocras | From 2023 onward | Expand WGS applications for patients with cancer |
MRD detection requires identifying extremely rare circulating tumor DNA (ctDNA) molecules within a large background of DNA.
For example, when the variant allele frequency is approximately 10^-6, simply generating more sequencing reads is insufficient.
PCR errors, sequencing errors, and DNA damage must be distinguished from genuine variants while maintaining extremely high specificity.
Ultima therefore began combining low-cost, high-volume sequencing with its high-accuracy rare variant detection technology, ppmSeq.
This marked a change in its value proposition.
Instead of merely supplying sequencing reads at a lower price, the company sought to enable highly sensitive assays that had previously been difficult to perform economically.
In April 2026, MRD data associated with TRACERx were presented at the AACR Annual Meeting, with initial results suggesting ctDNA detection sensitivity in the low single-digit parts-per-million range.
However, these preliminary results should not be interpreted as proof of performance in large prospective clinical trials.
4.4 2025: Proteomics Emerges as an Important Market
One of the most significant developments in Ultima's 2025 business strategy was its expansion into proteomics.
At first glance, a DNA sequencing company entering proteomics may seem unusual.
However, DNA barcode-based proteomics technologies, such as Olink Explore, quantify proteins by sequencing DNA molecules associated with protein detection events.
In this setting, NGS functions less as a tool for identifying nucleotide variants and more as a platform for counting vast numbers of molecular barcodes.
This is particularly well suited to Ultima's technical strengths.
UK Biobank Pharma Proteomics Project
In 2025, Ultima's UG 100 was selected as the sequencing platform for a large-scale proteomics project.
The project targeted approximately 600,000 samples and used Olink Explore HT to measure roughly 5,300–5,400 proteins.
The UK Biobank 2025 annual report also confirms the use of Olink Explore HT in combination with the UG 100.
According to the report, a pilot batch of approximately 12,000 samples was supplied to the Regeneron Genetics Center in March 2025, with data returned to UK Biobank in June.
Following initial quality assessments, sample delivery for the full-scale project proceeded. [10][11]
Regeneron Genetics Center
In June 2025, the UG 100 was also selected for a large-scale proteomics study involving approximately 200,000 serum samples originating from a collaborative research program between Regeneron Genetics Center and Geisinger.
Together with the approximately 600,000 samples in the UK Biobank project, these initiatives represent substantial adoption in population-scale proteomics. [12]
These developments are stronger market signals than partnership announcements alone.
The confirmation of UG 100 adoption in UK Biobank's own public materials is particularly important.
Ultima has increasingly moved from the position of a company that "sequences human genomes cheaply" toward becoming a provider of sequencing infrastructure for ultra-large-scale biological measurement.
4.5 2026: Population-Scale Multi-Omics and AI-Ready Data Generation
This direction became even more apparent in 2026.
A representative example is the Precure initiative involving Mayo Clinic and Thermo Fisher Scientific.
In September 2026, Ultima announced that its UG200 Ultra had been selected to support the generation of multi-omics data at a scale of approximately one million samples.
The initiative aims to integrate WGS, proteomics, and longitudinal clinical data for applications such as identifying early signs of disease and supporting drug discovery. [13]
Mayo Clinic also selected Helix as a multi-omics laboratory and AI tools provider.
Within this broader ecosystem, Ultima serves as a technology platform for large-scale sequencing.
Importantly, Ultima does not itself provide every assay, clinical service, or AI analysis required by these initiatives.
Instead, it aims to provide high-throughput data generation infrastructure that established testing companies, research institutions, and omics technology providers can use.
4.6 Summary of the Evolution in Application Focus
The company's changing priorities can be summarized as follows.
| Period | Strategic Focus | Main Technologies and Applications |
|---|---|---|
| 2016–2022 | Core technology development | DNA sequencing architecture, $100 genome |
| 2022–2024 | High-throughput research applications | WGS, scRNA-seq, epigenetics, MRD |
| 2025–2026 | Large-scale molecular measurement infrastructure | Population genomics, proteomics, oncology, AI-ready multi-omics |
These phases do not mean that one application was abandoned when another emerged.
Rather, Ultima expanded its business by adding applications while gradually broadening its strategic focus.
5. Evolution of the Service Delivery Model
Ultima's evolution was not limited to instruments and applications.
The way the company delivered its technology to customers also changed.
| Stage | Delivery Model | Strategic Objective |
|---|---|---|
| Before 2022 | Early access for major research institutions | Generate validation data and establish credibility |
| 2022–2023 | Limited instrument access and joint development | Develop applications and bioinformatics pipelines |
| 2024 | Commercial UG 100 instrument sales | Deploy systems in large sequencing facilities |
| 2025 | Expansion of Certified Service Provider network | Extend access to customers without instruments |
| 2025–2026 | Technology Access Program and partner collaborations | Lower barriers to adoption through internal instruments and external services |
| 2026 | UG200 series with flexible wafer configurations | Support customers with different throughput and infrastructure requirements |
In February 2025, Ultima announced service provider partnerships involving Broad Clinical Labs, Eurofins, Novogene, Psomagen, and the Ontario Institute of Cancer Research.
These joined existing service provider relationships involving organizations such as Macrogen, Inocras, and the University of Minnesota Genomics Center. [14]
There is an important economic rationale behind this evolution.
High-throughput sequencers can deliver strong cost advantages when operated near capacity.
However, laboratories with insufficient sample volumes may struggle to achieve favorable economics after investing in the instruments.
In addition, adopting a new sequencing platform requires more than purchasing equipment.
Customers must address bioinformatics workflows, maintenance, staff training, and transitions from existing experimental protocols.
By concentrating instrument operation within specialized service providers, Ultima can make low-cost sequencing accessible to small and medium-sized research groups.
At the same time, service providers can aggregate demand and maintain higher instrument utilization.
For Ultima, this creates ongoing demand for wafers, reagents, and other consumables.
Its commercial model has therefore evolved toward a combination of direct instrument sales, recurring consumables revenue, and expanded access through service providers.
6. Evolution of Leadership and Organization
Publicly available information suggests that Ultima evolved from an R&D-centered organization into a company with increasingly specialized manufacturing, quality, commercial, and application-focused functions.
6.1 Early Organization: Combining Physics, Engineering, and Genomics
Alongside founder Gilad Almogy, one of the important early scientific leaders was Doron Lipson, who served as Chief Scientific Officer.
Researchers including Lipson, Florian Oberstrass, and Omer Barad appeared in Ultima's early technology publications and scientific presentations. [2]
The company's early technical capabilities appear to have combined the following areas:
- Semiconductor engineering, precision instrumentation, and applied physics
- Molecular biology and sequencing chemistry
- Bioinformatics and algorithm development
- Engineering of large-scale instruments and consumables
A June 2022 report in the Israeli business newspaper Globes stated that Ultima employed approximately 350 people, including around 50 in Israel.
The company also maintained development facilities in Rehovot and Hod Hasharon. [15]
Having several hundred employees only six years after founding suggests substantial investment in hardware engineering and R&D compared with many conventional early-stage biotechnology startups.
6.2 2023: Recruiting Leadership for Commercialization
In June 2023, Ultima announced two important leadership appointments. [16]
Mirna Jarosz — Head of Product Strategy
Jarosz joined with experience leading the NGS business at Integrated DNA Technologies (IDT).
Her responsibilities included product strategy, marketing, customer applications, and adoption.
Shlomey Derhi — Head of Architecture and Integration
Derhi joined with leadership experience in large-scale R&D organizations within the Israel Defense Forces.
His role focused on technology development and system integration.
These appointments were strategically significant.
Jarosz addressed the challenge that developing a technically excellent instrument is not sufficient for commercial success.
Customers must understand its applications, economics, and integration requirements.
Derhi brought capabilities relevant to integrating complex technologies into stable commercial products.
6.3 2024: Strengthening Manufacturing, Quality, and Commercial Operations
In August 2024, Ultima announced the recruitment of Chris Seipert and Lara Toerien.
Seipert had spent approximately 14 years at PacBio, holding senior positions in manufacturing, service, and regional business operations.
At Ultima, he was appointed to lead Operations, including instrument and consumables production, quality management, and initiatives toward ISO certification. [17]
This was another important organizational transition.
The challenge for a large scientific instrument manufacturer is not simply producing a prototype capable of generating impressive data.
It must consistently deliver reliable performance after dozens or hundreds of systems have been installed.
Consumables must be available with predictable quality, and customers must receive appropriate maintenance and service support.
Expertise in manufacturing and quality systems therefore becomes essential as an R&D organization transitions into a precision instrument manufacturer.
6.4 2025–2026: Regional and Application-Specific Organizations
Subsequent appointments reflected continued organizational specialization.
In October 2025, Jason Kang was appointed to lead business development in Asia.
In February 2026, Elena Helman joined to strengthen oncology-related activities.
In May 2026, Francisco De La Vega, an expert in germline genomics, also joined the company.
As of November 2026, the company's publicly listed leadership included the following individuals. [4]
| Name | Position | Main Responsibility |
|---|---|---|
| Gilad Almogy | Founder & CEO | Corporate strategy and leadership |
| David Peoples | Chief Financial & Business Officer | Finance and business operations |
| Toni Lin | Chief Administrative Officer | Corporate administration |
| Chris Seipert | SVP, Operations | Manufacturing and operations |
| Omer Barad | SVP, Genomic Solutions | Genomic solutions |
| Florian Oberstrass | SVP, Technology Development | Technology development |
| Shlomey Derhi | SVP, Engineering & Product Integration | Product integration |
| Francisco De La Vega | VP, Germline Genomics | Germline genomics and WGS |
| Elena Helman | VP, Oncology Solutions | Oncology |
| Jason Kang | GM, Asia | Asian regional business |
Two patterns emerge from these organizational developments.
First, Ultima maintained its core technological capabilities while adding expertise in manufacturing, commercial operations, and regional market development.
Second, the company increasingly incorporated application-specific expertise in areas such as germline genomics, oncology, and gene expression.
However, the ability to trace executive appointments should not be confused with having a complete picture of organizational change.
Public information remains insufficient to reconstruct annual employee counts, turnover rates, internal reorganizations, or the reasons for departures of certain early executives.
It would therefore be inappropriate to interpret particular departures as evidence of management failures or internal conflicts without supporting information.
7. Evolution of Financing and Capital Structure
7.1 Early Financing: Not a Typical Capital-Light Startup
Ultima attracted substantial venture investment from its early years.
Lightspeed Venture Partners identifies its initial investment as dating to 2016, while Playground Global states that it co-led the company's Series A financing in 2017.
The company continued raising capital privately and had accumulated approximately $600 million in funding by the time it emerged from stealth in 2022. [1]
It is important not to interpret the $600 million figure as a single financing round completed in 2022.
Rather, it represented cumulative capital raised over several years of development.
7.2 Major Investors
Ultima's publicly disclosed investors include the following.
| Investor | Role or Background |
|---|---|
| Lightspeed Venture Partners | Early investor beginning in 2016 |
| Playground Global | Co-lead investor in the 2017 Series A |
| Khosla Ventures | Investor focused on deep technology |
| Andreessen Horowitz | Participant in major financing |
| General Atlantic | Growth-oriented investor |
| Founders Fund | Investor in technology-driven companies |
| D1 Capital Partners | Publicly disclosed investor |
| aMoon | Life sciences-focused investor |
| Marius Nacht | Israeli entrepreneur and investor |
These investors were also identified in the company's 2022 announcement. [1]
The investor group is consistent with the idea that Ultima has been evaluated less as a conventional diagnostics startup and more as a capital-intensive technology platform company resembling precision semiconductor equipment businesses.
7.3 Financing Developments After 2022
| Period | Publicly Reported Funding | Notes |
|---|---|---|
| 2016 | Seed investment | Amount not sufficiently confirmed |
| 2017 | Series A | Co-led by Playground and others |
| May 2022 | Approximately $600 million cumulative | Announced upon emerging from stealth |
| November 2026 | More than $700 million cumulative | Figure reported on the company's website |
This implies that cumulative funding increased by at least approximately $100 million between 2022 and 2026.
However, publicly available information does not allow a reliable reconstruction of all financing round dates, amounts contributed by individual investors, valuations, or the breakdown between equity and debt.
Startup databases also report different cumulative funding figures, including approximately $600 million, $614 million, and more than $700 million.
These discrepancies may reflect different update schedules or definitions of included funding, but their precise causes cannot be established. [1][4]
7.4 Evaluating Capital Efficiency
One of the most important financial questions is whether Ultima can generate economic returns commensurate with its substantial upfront investment.
However, as a privately held company, it does not publicly disclose enough information to reliably assess several critical metrics:
- Revenue, gross margins, and operating income or losses
- Cumulative installations of UG 100 and UG200 systems
- Annual wafer consumption per installed instrument
- Revenue mix between instruments and consumables
- Cash holdings and cash runway
- Details of additional financing, dilution, or debt
As a result, it is possible to evaluate the company's technological achievements and progress in customer adoption, but there is insufficient evidence to conclude that Ultima has already achieved financial success.
Some startup databases publish estimates of company valuation.
Such estimates should be distinguished from confirmed valuations associated with actual financing transactions.
8. Major Challenges and How Ultima Addressed Them
Ultima's development can be analyzed through six major challenges spanning technology, products, manufacturing, and commercialization.
8.1 Challenge 1: Accuracy Limitations Associated with a Different Sequencing Chemistry
Ultima's mnSBS chemistry uses predominantly natural nucleotides in a non-terminating extension process.
Although this provides advantages in cost and throughput, it also produces an error profile different from conventional SBS.
For example, homopolymer regions can create challenges when determining the number of consecutive identical bases incorporated during a reaction.
The 2022 scRNA-seq comparison study also reported reduced UMI quality associated with poly(T) regions near the 3′ end. [2]
How Ultima Responded
The company improved library-dependent preprocessing, UMI trimming, base-calling algorithms, amplification methods, and sequencing chemistry.
The UG200 generation also emphasizes improved coverage uniformity. [9]
Assessment: Substantial improvement, but application-specific validation remains necessary.
SNVs, indels, structural variants, difficult genomic regions, and GC bias cannot all be assessed using a single sequencing accuracy metric.
Independent comparisons with Illumina and other platforms using current-generation instruments and reference datasets such as Genome in a Bottle (GIAB) remain important.
8.2 Challenge 2: Single-End Sequencing and Compatibility with Existing Workflows
The original UG 100 presented obstacles for customers migrating from established Illumina-based workflows.
Cornell University's sequencing service documentation explained that the UG 100 originally generated single-end reads and that bioinformatics approaches could split these reads into paired-end-like formats.
It also described the need for additional PCR steps to convert adapters in standard Illumina-style libraries.
These requirements represented meaningful constraints for WGS, structural variant analysis, and existing clinical bioinformatics pipelines.
How Ultima Responded
In October 2026, Ultima commercialized paired-end sequencing on the UG200 platform.
The company also continued improving Solaris 2.0 and associated library preparation workflows. [5][9]
Assessment: An important product limitation has been addressed, but complete interoperability still requires validation.
The announcement of paired-end capability does not mean that all existing Illumina-based assays can immediately be transferred without modification.
Migration costs and validation requirements will continue to vary by application.
8.3 Challenge 3: Ultra-High Throughput Requires Enormous Sample Demand
The ability to sequence tens of thousands of genomes per year on a single instrument can be a major advantage when sufficient demand exists.
However, laboratories with lower sample volumes may struggle to achieve attractive economics from such instruments.
How Ultima Responded
The company pursued several strategies:
- Aggregating sequencing demand through Certified Service Providers
- Expanding into read-intensive applications such as single-cell analysis and proteomics
- Offering flexible single-wafer and dual-wafer configurations through the UG200 series
- Providing opportunities to access technology before instrument purchase through its Technology Access Program
Assessment: The strategy is economically rational, and substantial projects have been secured.
The UK Biobank and Regeneron projects are particularly relevant examples.
However, Ultima has not publicly disclosed the average utilization rate across its installed instrument base.
8.4 Challenge 4: Transitioning from an R&D Company into a Manufacturing Business
Successful early technology development does not automatically create a sustainable sequencing platform business.
Manufacturing yield, consumable lot-to-lot consistency, maintenance, and field service are critical.
How Ultima Responded
The company strengthened manufacturing and quality management capabilities, notably through the recruitment of Chris Seipert in 2024.
The UG200 platform also introduced instrument simplification, automation, a smaller footprint, and more standardized workflows. [9][17]
Assessment: Ultima has taken concrete organizational and product-level steps.
Nevertheless, the company's manufacturing costs, yields, and field failure rates are not publicly available.
Its manufacturing maturity therefore cannot be reliably assessed quantitatively.
8.5 Challenge 5: Establishing Credibility in Clinical Markets
Clinical NGS applications require more than accurate sequencing.
They also require validated assay performance, clinical validity, quality management, regulatory compliance, and reliable reporting systems.
How Ultima Responded
Rather than building every aspect of the clinical testing business internally, Ultima collaborated with established organizations such as Quest Diagnostics, Labcorp, and Broad Clinical Labs.
This potentially allows Ultima to focus on sequencing technology while partners contribute expertise in assay development, validation, and clinical service delivery.
Assessment: Market entry through partnerships has progressed, but widespread clinical adoption remains to be demonstrated.
In MRD applications, for example, analytical sensitivity alone is insufficient.
False-positive rates, longitudinal reproducibility, and the impact of test results on patient management must also be evaluated.
8.6 Challenge 6: Competing with Illumina's Established Ecosystem
One of Ultima's most significant commercial challenges is the enormous installed base and ecosystem surrounding Illumina.
Illumina's competitive advantages extend beyond instrument performance.
They include library preparation reagents, bioinformatics pipelines, published research, clinical validation, and established laboratory expertise.
Competing technologies have also continued to improve their products and pricing while Ultima has pursued lower costs.
How Ultima Responded
Rather than attempting to replace all Illumina applications immediately, Ultima appears to have focused first on applications where its low-cost, high-throughput architecture offers particularly strong advantages.
This strategy aligns with its expansion from WGS into single-cell analysis, proteomics, and MRD.
Assessment: Ultima has secured adoption in differentiated applications, but it has not demonstrated that it can replace the broader established sequencing ecosystem.
9. What Has Ultima Achieved, and What Remains Unresolved?
Based on its development through 2026, Ultima's progress can be summarized as follows.
| Area | Assessment |
|---|---|
| Commercialization of a proprietary sequencing architecture | Achieved |
| Commercial introduction of the advertised $60 genome | Announced and commercialized |
| Adoption in large-scale research projects | Demonstrated |
| Broad compatibility with established NGS workflows | Improving |
| Widespread adoption in clinical applications | Still undergoing validation and expansion |
| Profitability and sustainable capital efficiency | Insufficient public information |
These assessments are based on product announcements, adoption by research institutions, scientific publications, and statements from partners.
In particular, evidence of customer adoption does not necessarily establish the commercial value of contracts, the volume of completed samples, or the revenue generated.
Technological competitiveness, market adoption, and profitability must therefore be evaluated separately.
10. Evaluating Ultima Genomics' Business Strategy
The following sections offer an interpretation based on the publicly available evidence.
10.1 The Strongest Element Was the Alignment Between Technology and Market Strategy
Ultima selected commercial applications in which its early technology could deliver value even without outperforming established NGS platforms across every metric.
For example, single-cell expression profiling and DNA barcode-based proteomics require enormous numbers of reads but do not necessarily require the same type of variant-calling accuracy demanded by WGS.
In such markets, reducing the cost per read can create substantial value.
At the same time, Ultima progressively addressed the greater accuracy and compatibility requirements of germline WGS and clinical applications through ppmSeq, Solaris 2.0, paired-end sequencing, and improved amplification chemistry.
This illustrates a growth strategy in which a company first targets markets aligned with its technological strengths, then expands its application range as it addresses its limitations.
10.2 Collaboration with Research Institutions Became a Competitive Asset
Early collaborations with institutions such as the Broad Institute were likely important for more than promotional purposes.
New sequencing chemistries create different biases and error profiles, often requiring the development or adaptation of bioinformatics methods.
Generating data with leading research institutions and publishing scientific studies provides several benefits:
- Identifying technological limitations
- Improving bioinformatics algorithms and workflows
- Building credibility among potential customers
These early validation efforts may have contributed to subsequent collaborations involving Quest, Labcorp, Regeneron, and UK Biobank-related projects.
However, the specific causal role of those studies in securing individual commercial agreements cannot be established from public information.
10.3 Repositioning Sequencing as Molecular Measurement Infrastructure
This may be one of the most important strategic developments affecting Ultima's future.
Traditionally, the NGS market has been understood primarily as a market for reading DNA and RNA sequences.
However, modern molecular biology increasingly uses DNA barcodes to measure protein abundance, gene expression in individual cells, genetic perturbations, spatial molecular information, and other biological features.
In these applications, the role of a sequencer extends beyond conventional nucleotide sequence determination.
A platform capable of reading enormous numbers of DNA barcodes at low cost could potentially serve many different omics technologies.
Ultima appears to be positioning itself to capture this expanding market.
10.4 Commercial Economics May Be a Greater Long-Term Risk Than Technology Development
Instrument utilization is likely to be as important as sequencing performance when evaluating Ultima's future.
Even if a sequencing system can process tens of thousands of genomes annually, its economics may deteriorate if customers do not generate enough samples to use that capacity.
Likewise, offering low-cost sequencing consumables does not necessarily mean that Ultima itself generates attractive profits.
Important indicators include not only cumulative instrument installations but also:
- Total wafer consumption
- Average instrument utilization
- Repeat usage by customers
- Gross margins on consumables
If these indicators grow sustainably, there would be stronger evidence that Ultima's technological competitiveness is translating into commercial competitiveness.
11. Key Indicators to Monitor Going Forward
Five indicators will be particularly important for evaluating Ultima in the coming years.
| Indicator | What to Examine | Why It Matters |
|---|---|---|
| Commercial adoption of UG200 | Cumulative installations and active operating sites | Reveals actual demand for the product |
| Consumables utilization | Wafer consumption and repeat usage | Indicates growth in recurring revenue |
| Paired-end WGS quality | Comparative performance for SNVs, indels, SVs, and difficult genomic regions | Indicates potential penetration of established sequencing markets |
| Progress of large-scale research projects | Actual sample throughput and contract renewals | Demonstrates commercial and operational execution |
| Financing and financial performance | Additional funding, revenue, and cash consumption | Indicates long-term financial sustainability |
In particular, the performance of the UG200 and Solaris 2.0 Max in real-world customer operations during 2027 and beyond may represent an important turning point.
For a deeper technical assessment, it would also be valuable to examine GIAB benchmarking of UG200-generation data, compatibility with DeepVariant and pangenome-aware analysis, and independent validation of the error suppression mechanisms and detection limits of ppmSeq.
12. Conclusion: What Ultima Genomics' First Decade Reveals
Ultima Genomics' first decade can be understood through three major transitions.
First, the company brought semiconductor and precision instrumentation concepts into genomics to develop a fundamentally different low-cost sequencing architecture.
Founder Gilad Almogy applied expertise from semiconductor manufacturing equipment, including large-scale processing, systems integration, and automation, to DNA sequencing.
Through approximately six years of stealth development and substantial venture financing, Ultima established a platform combining open fluidics and mnSBS.
Second, Ultima converted its research achievements into a commercial product through scientific validation and substantial capital investment.
Early studies with the Broad Institute and other research institutions helped establish credibility while identifying technical challenges and supporting application development.
The commercial launch of the UG 100 in 2024 marked the company's transition from a technology development organization into a sequencing instrument manufacturer.
Third, Ultima expanded into oncology, single-cell biology, proteomics, and population-scale genomics while improving its instruments, chemistry, and analytical methods.
Through successive product generations, the company addressed not only sequencing costs but also paired-end compatibility, simplified amplification, reduced instrument size, and greater flexibility for customers with different throughput requirements.
One of Ultima's most important strategic decisions was not attempting to outperform established platforms across every application from the beginning.
Instead, it initially focused on applications where low cost and extremely high throughput provided the greatest advantages, then expanded its addressable markets as its technology matured.
At the same time, although substantial evidence supports the company's technological progress and product commercialization, public information remains insufficient to determine whether it has established a sustainably profitable business model.
Ultimately, Ultima's potential to transform the genomics industry will depend less on the ability to sequence a genome for $60 than on whether it can become a standard platform that customers continuously rely on for large-scale molecular measurement.
References
[1] Ultima Genomics, “Ultima Genomics Delivers the $100 Genome. Emerges from Stealth with $600 Million in Funding,” May 31, 2022. https://www.ultimagenomics.com/blog/ultima-genomics-delivers-the-usd100-genome/
[2] Simmons, S. K., Lithwick-Yanai, G., Adiconis, X., et al., “Mostly natural sequencing-by-synthesis for scRNA-seq using Ultima sequencing,” Nature Biotechnology, 41, 204–211, 2023 (published online September 15, 2022). https://doi.org/10.1038/s41587-022-01452-6
[3] Almogy, G., et al., “Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform,” bioRxiv, 2022. https://doi.org/10.1101/2022.05.29.493900
[4] Ultima Genomics, “About Us,” Company Website (accessed November 3, 2026). https://www.ultimagenomics.com/about-us/
[5] Ultima Genomics, “Ultima Genomics Launches Paired-End Sequencing and Solaris 2.0 Max at ASHG 2026, Doubling Output and Enabling the $60 Genome,” PR Newswire, October 20, 2026. https://www.prnewswire.com/news-releases/ultima-genomics-launches-paired-end-sequencing-and-solaris-2-0-max-at-ashg-2026--doubling-output-and-enabling-the-60-genome-302914208.html
[6] Ultima Genomics, “Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris,” PR Newswire, February 24, 2025. https://www.prnewswire.com/news-releases/ultima-genomics-increases-output-by-over-50-and-lowers-sequencing-costs-by-a-further-20-with-the-introduction-of-ug-100-solaris-302382977.html
[7] SolarEdge Technologies, “Gilad Almogy,” Board Member Biography. https://investors.solaredge.com/board-member-committee-member/gilad-almogy
[8] Bio-IT World, “Ultima's Silicon Wafer Sequencing Launches on $100 Genome, Part Per Million Accuracy,” February 27, 2024. https://www.bio-itworld.com/news/2024/02/27/ultima-s-silicon-wafer-sequencing-launches-on-100-genome-part-per-million-accuracy
[9] Ultima Genomics, “UG200 Series: Ultra High-Throughput Sequencing Platform,” Product Website. https://www.ultimagenomics.com/products/ug200-series/
[10] UK Biobank, “Launch of world's most significant protein study set to usher in new understanding for medicine,” January 10, 2025. https://www.ukbiobank.ac.uk/news/launch-of-worlds-most-significant-protein-study-set-to-usher-in-new-understanding-for-medicine/
[11] UK Biobank Limited, Report and Financial Statements 2025, 2025. https://www.ukbiobank.ac.uk/wp-content/uploads/2026/01/UK-Biobank-annual-report-2025.pdf
[12] Ultima Genomics, “Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center,” PR Newswire, June 26, 2025. https://www.prnewswire.com/news-releases/ultima-genomics-selected-to-support-the-worlds-largest-proteomics-studies-to-date-led-by-regeneron-genetics-center-302492524.html
[13] Ultima Genomics, “Ultima Genomics Selected to Generate One Million-Sample, World-Leading Multi-omic Biomedical Dataset for AI/ML Precure, LLC Initiative,” PR Newswire, September 22, 2026. https://www.prnewswire.com/news-releases/ultima-genomics-selected-to-generate-one-million-sample-world-leading-multi-omic-biomedical-dataset-for-aiml-precure-llc-initiative-302885572.html
[14] Ultima Genomics, “Ultima Genomics expands global access to high-quality, low-cost DNA sequencing on the UG 100 sequencing platform through partnerships with multiple premier genomic services providers,” PR Newswire, February 25, 2025. https://www.prnewswire.com/news-releases/ultima-genomics-expands-global-access-to-high-quality-low-cost-dna-sequencing-on-the-ug-100-sequencing-platform-through-partnerships-with-multiple-premier-genomic-services-providers-302384224.html
[15] Weinreb, G., “Genome sequencing co Ultima Genomics raises $600m,” Globes, June 2, 2022. https://en.globes.co.il/en/article-genome-sequencing-co-ultima-genomics-raises-600m-1001414037
[16] Ultima Genomics, “Ultima Genomics Adds Tenured Strategic and Technology Leadership In Preparation for Commercial Launch,” PR Newswire, June 26, 2023. https://www.prnewswire.com/news-releases/ultima-genomics-adds-tenured-strategic-and-technology-leadership-in-preparation-for-commercial-launch-301861344.html
[17] Ultima Genomics, “Ultima Genomics adds tenured leadership to drive operational excellence and commercial adoption,” PR Newswire, August 13, 2024. https://www.prnewswire.com/news-releases/ultima-genomics-adds-tenured-leadership-to-drive-operational-excellence-and-commercial-adoption-302220980.html
[18] Ultima Genomics, “Ultima Genomics Introduces the Next Generation of Sequencing at Scale with the Launch of the UG200 Series and Next Generation Solaris 2.0 Workflows,” PR Newswire, February 2026. https://www.prnewswire.com/news-releases/ultima-genomics-introduces-the-next-generation-of-sequencing-at-scale-with-the-launch-of-the-ug200-series-and-next-generation-solaris-2-0-workflows-delivering-higher-output-better-performance-and-more-flexible-wafer-configuratio-302694374.html